Dechra Pharmaceuticals PLC represents a set of core values and a corporate philosophy that sets them apart in the pharmaceutical industry. With a strong focus on innovation, Dechra strives to improve animal health worldwide. Their commitment to research and development enables them to provide effective and safe veterinary products. Dechra emphasizes ethical behavior, transparency, and accountability in all their operations. They prioritize collaboration, both internally and externally, to foster strong partnerships and drive mutual success. By putting animals' well-being at the forefront, Dechra Pharmaceuticals PLC aims to make a positive impact on the lives of pets and livestock.

Dechra Pharmaceuticals PLC is primarily present in multiple countries and regions. Some key regions where the company operates include North America, Europe, and Australia. In North America, Dechra Pharmaceuticals has a strong presence in the United States and Canada. In Europe, the company operates in countries such as the United Kingdom, Germany, France, Spain, Italy, and others. Additionally, Dechra Pharmaceuticals has a significant presence in Australia. Through its global presence, Dechra Pharmaceuticals PLC continues to expand its reach and provide veterinary pharmaceutical products and services to various markets worldwide.

Dechra Pharmaceuticals PLC has achieved several significant milestones over the years. Firstly, in 2007, the company successfully acquired VetXX, expanding its product portfolio and strengthening its presence in the companion animal veterinary market. Additionally, in 2010, Dechra Pharmaceuticals acquired Eurovet Animal Health BV, further enhancing its product range and market reach. The company also achieved a major milestone in 2017 by receiving FDA approval for Zycortal, a treatment for canine Addison's disease. Furthermore, in 2019, Dechra Pharmaceuticals launched Osphos, a unique and innovative treatment for navicular syndrome in horses. These milestones highlight Dechra Pharmaceuticals PLC's commitment to continuous growth, product innovation, and expansion within the animal healthcare industry.

Dechra Pharmaceuticals PLC is a leading veterinary pharmaceutical company headquartered in the United Kingdom. Established in 1997, Dechra has built a strong reputation in developing, manufacturing, and marketing a wide range of specialized veterinary medicines and related products. With a focus on enhancing the well-being of animals and improving their quality of life, Dechra is dedicated to providing innovative solutions to veterinarians and pet owners worldwide. Over the years, it has expanded its presence globally and now operates in various countries. Dechra Pharmaceuticals PLC continues to strive for excellence in the field of veterinary healthcare, delivering high-quality products and driving advancements in animal medicine.

The main competitors of Dechra Pharmaceuticals PLC in the market include companies such as Zoetis Inc., IDEXX Laboratories, Inc., Covetrus, Inc., and Virbac SA. These companies also operate in the animal healthcare industry and provide similar products and services. However, Dechra Pharmaceuticals PLC distinguishes itself through its unique product portfolio, strong distribution network, and focus on specialized veterinary medicine. With its commitment to innovation and customer-centric approach, Dechra Pharmaceuticals PLC successfully competes against these industry players to maintain its market position.

Dechra Pharmaceuticals PLC is primarily active in the veterinary healthcare industry.

Dechra Pharmaceuticals PLC operates under a business model focused on the research, development, production, and marketing of veterinary pharmaceutical products. The company specializes in providing innovative solutions for veterinarians and pet owners, offering a wide range of prescription medications and other healthcare products for companion animals and livestock. Dechra Pharmaceuticals PLC strives to enhance animal health and welfare by delivering high-quality pharmaceuticals and supporting solutions. With its strong commitment to the veterinary industry, Dechra Pharmaceuticals PLC continues to contribute to the well-being of animals worldwide.

Dechra Pharmaceuticals의 P/E 비율은 29.69입니다.

Dechra Pharmaceuticals의 P/S 비율은 5.15입니다.

Dechra Pharmaceuticals에 대한 AlleAktien 품질 점수는 4/10입니다.

예상되는 Dechra Pharmaceuticals 매출은 851.26 백만 GBP입니다.

예상되는 Dechra Pharmaceuticals 이익은 147.77 백만 GBP입니다.

Dechra Pharmaceuticals PLC is a globally operating animal pharmaceutical company based in the United Kingdom. Its core business consists of the development, manufacturing, and marketing of animal medications and equipment. The company operates in Europe, North America, and Australasia, employing over 2,200 people worldwide. The company is divided into several business divisions: Pharmaceuticals: In this area, Dechra offers a wide range of animal medicines, including veterinary medicines for pets such as dogs and cats, as well as for livestock such as pigs, cattle, and sheep. The range includes medications for infectious diseases, as well as inflammatory diseases, metabolic disorders, and cancer. Medical devices: The Medical Devices division is involved in the development, production, and marketing of medical devices and consumables for veterinary practices and clinics. This includes surgical instruments, catheters, syringes, and needles, for example. Services: Dechra offers services related to animal medicine, including continuing education for veterinarians, consulting for veterinary practices in setting up laboratories, and support for veterinary practices in the management of medications and instruments. Dechra's core business is the sale of animal medications. The company is committed to expanding its position as a leading provider of animal medications. To this end, Dechra invests heavily in research and development to develop new medications and improve existing ones. In addition, the company has made several acquisitions in recent years to expand its product portfolio and increase its global presence. An example of an acquisition is the purchase of Putney Inc. in 2016. Putney is a leading provider of animal medications for pets in the United States. With this acquisition, Dechra was able to strengthen its presence in the North American market and expand its portfolio of animal medications for dogs and cats. Another important factor for Dechra's success is its close collaboration with veterinarians. The company works closely with veterinarians to develop new medications and improve existing ones. Dechra also offers veterinarians continuing education to ensure they are always up to date with veterinary medicine. Overall, Dechra's business model is focused on supporting veterinarians in the treatment of animals. The company offers a broad portfolio of animal medications, medical devices, and services, and continually invests in research and development to ensure it provides the veterinary profession with the right solutions. With its global presence and close collaboration with veterinarians, Dechra is well positioned to continue to be successful in the future.

Dechra Pharmaceuticals은(는) 연간 번의 배당을 통해 0.45 GBP의 배당금을 지급합니다.

Dechra Pharmaceuticals의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Dechra Pharmaceuticals의 ISIN은 GB0009633180입니다.

Dechra Pharmaceuticals의 WKN은 578968입니다.

Dechra Pharmaceuticals의 티커는 DPH.L입니다.

지난 12개월 동안 Dechra Pharmaceuticals은(는) 0.25 GBP 의 배당금을 지급했습니다. 이는 약 0.65 %의 배당 수익률에 해당합니다. 향후 12개월 동안 Dechra Pharmaceuticals은(는) 0.25 GBP의 배당금을 지급할 것으로 예상됩니다.

Dechra Pharmaceuticals의 현재 배당 수익률은 0.65 %입니다.

Dechra Pharmaceuticals은 분기별로 배당금을 지급합니다. 이는 , , , 월에 배당됩니다.

Dechra Pharmaceuticals은(는) 지난 25년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0.25 GBP의 배당금이 예상됩니다. 이는 배당수익률 0.65 %에 해당합니다.

Dechra Pharmaceuticals은 '건강' 섹터에 속합니다.

Dechra Pharmaceuticals의 마지막 배당금을 0.125 GBP만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Dechra Pharmaceuticals는 0.449 GBP를 배당금으로 지급했습니다.

Dechra Pharmaceuticals의 배당금은 GBP에 지급됩니다.